Comparison between orlistat plus l-carnitine and orlistat alone on inflammation parameters in obese diabetic patients

Fundam Clin Pharmacol. 2011 Oct;25(5):642-51. doi: 10.1111/j.1472-8206.2010.00888.x. Epub 2010 Nov 16.

Abstract

To evaluate the effects of 1-year treatment with orlistat plus L-carnitine compared to orlistat alone on body weight, glycemic and lipid control, and inflammatory parameters in obese type 2 diabetic patients. Two hundred and fifty-eight patients with uncontrolled type 2 diabetes mellitus (T2DM) [glycated hemoglobin (HbA(1c)) > 8.0%] in therapy with different oral hypoglycemic agents or insulin were enrolled in this study and randomized to take orlistat 120 mg three times a day plus L-carnitine 2 g one time a day or orlistat 120 mg three times a day. We evaluated the following parameters at baseline and after 3, 6, 9, and 12 months: body weight, body mass index (BMI), glycated hemoglobin (HbA(1c) ), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (Tg), adiponectin (ADN), leptin, tumor necrosis factor-α (TNF-α), vaspin, and high-sensitivity C-reactive protein (Hs-CRP). We observed a better decrease in body weight, glycemic profile, HOMA-IR, LDL-C, and ADN and a faster improvement in FPI, TC, Tg, leptin, TNF-α, Hs-CRP with orlistat plus L-carnitine compared to orlistat alone. We also recorded an improvement in vaspin with orlistat plus l-carnitine not reached with orlistat alone. Orlistat plus L-carnitine gave a better improvement in body weight, glycemic and lipid profile compared to orlistat alone; furthermore, a faster and better improvement in inflammatory parameters was observed with orlistat plus L-carnitine compared to orlistat alone.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adiponectin / blood
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / adverse effects
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use
  • Anti-Obesity Agents / administration & dosage
  • Anti-Obesity Agents / adverse effects
  • Anti-Obesity Agents / pharmacology
  • Anti-Obesity Agents / therapeutic use*
  • Blood Glucose / metabolism
  • Body Mass Index
  • Body Weight
  • C-Reactive Protein / metabolism
  • Carnitine / administration & dosage
  • Carnitine / adverse effects
  • Carnitine / pharmacology
  • Carnitine / therapeutic use*
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Female
  • Glycated Hemoglobin / analysis
  • Glycated Hemoglobin / metabolism
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / pharmacology
  • Hypoglycemic Agents / therapeutic use*
  • Inflammation / drug therapy
  • Inflammation / physiopathology
  • Insulin / blood
  • Insulin Resistance / physiology
  • Lactones / administration & dosage
  • Lactones / adverse effects
  • Lactones / pharmacology
  • Lactones / therapeutic use*
  • Leptin / blood
  • Lipoproteins, HDL / blood
  • Lipoproteins, LDL / blood
  • Male
  • Middle Aged
  • Obesity / diet therapy
  • Obesity / drug therapy*
  • Obesity / metabolism
  • Orlistat
  • Thiazolidinediones / adverse effects
  • Thiazolidinediones / pharmacology
  • Time Factors

Substances

  • Adiponectin
  • Anti-Inflammatory Agents
  • Anti-Obesity Agents
  • Blood Glucose
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Lactones
  • Leptin
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Thiazolidinediones
  • C-Reactive Protein
  • Orlistat
  • Carnitine